Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


Alzheimer's Disease Research
Current Award

Dr. Guilian Xu

Guilian Xu, PhD

University of Florida
Gainesville, FL

Title: Protein Homeostasis in Mouse Models of Alzheimer’s Pathology
Non-Technical Title: Are There Global Changes in Protein Metabolism with Alzheimer’s Disease and Do These Changes Affect Cognition?

Duration: July 1, 2014 - June 30, 2017
Award Type: Standard
Award Amount: $249,703


We plan to investigate fundamental changes that occur in the way nerve cells manage the production of new proteins and the disposal of old proteins. This process is essential to the normal functioning of the brain. In prior work, we identified a new pathology associated with Alzheimer’s disease that we call secondary misfolding pathology, which occurs when enzymes and regulatory proteins lose solubility. In this proposal we will be working to better understand how this newly-discovered pathology may be affecting the ability of brain to function.


Alzheimer’s disease (AD) is the most common form of dementia in people over 65 years of age. There is no cure for it; in fact scientists have not found a cure for any neurodegenerative disease so far. The detailed mechanisms of the causes and progression of the disease are not completely understood. Under a microscope, AD patients’ brains show high levels of amyloid plaques (caused by accumulation of small piece of protein called Aβ) and tangles (filled with another insoluble protein, called tau). It is known that Aβ deposition is the fundamental cause of the disease, but we do not know how this first entity triggers the downstream changes in the brains, such as tangle formation and brain cell death, which is the direct cause of dementia.

For our research, we will investigate the global protein solubility changes during the conditions of high levels of Aβ or tau is forming. The process of cell handling protein metabolism is essential to the normal functioning of the brain. In work prior to this proposal, we have identified a new pathology associated with Alzheimer’s disease that we call “secondary misfolding,” which describes how some normally soluble proteins become insoluble when high levels of Aβ accumulate in the brain. In the mice that model familial cases of Alzheimer’s disease, we found accumulation of Aβ caused about 30 highly soluble proteins to lose their solubility. Many of these proteins are crucial to basic functions of the nerve cells. We do not know whether or not this change causes AD to progress.We hypothesize that tau protein is one of the “secondary misfolded” proteins that happens as human Alzheimer’s disease progresses, although in the mouse models, tau protein’s solubility did not change. In this proposal, we will investigate deeper to understand how “secondary misfolding” may affect the brain function. We will use two mouse models, one of which mimics amyloid plaques in the human brain and the other of which mimics neurofibrillary “tau tangles.” Both mouse models are genetically engineered to have their human disease protein production switched on or off by simply feeding them tetracycline. Using these models, we will find out how the newly produced amyloid or tau affects the balance of regular protein production and disposal that cells must handle. Based on the previous studies, in both models, once the human disease genes were switched off, the memory of the mice improved to close to normal levels. We wonder whether “secondary misfolding” of certain important proteins related to memory or/and cell survival holds the key to memory changes. If we can determine how stopping the production of the disease-related toxic proteins causes the brain function to return to normal, we may be able to predict how much benefit patients will derive from future drugs which can stop Aβ or tau production are developed.

Investigator Biography:

Guilian Xu is an Assistant Research Scientist in the Department of Neuroscience at the University of Florida. In 1996, she initiated her doctoral studies at The University of Hong Kong, focusing on neurotransmitter imbalances and cholinergic system dysfunction in Alzheimer’s disease (AD) mouse models. She finishing her PhD thesis working in the lab of David Borchelt, PhD, at Johns Hopkins’ Neuropathology division, then stayed as a postdoctoral fellow to continue her studies into the mechanism of AD and other neurodegenerative diseases, focusing in particular on protein aggregation. About a decade ago, Dr. Xu and her mentor, Dr. Borchelt, began investigating the hypothesis that a dysfunction in protein homeostasis as a shared mechanism behind neurodegenerative diseases. In order to study this, Dr. Xu, a former analytical biochemist, took mass spectrometry and bioinformatics courses at Johns Hopkins and then acquired training at the University of Florida on mass spectrometry instruments and related bioinformatics tools. She got her first research support in 2004, from The John Douglas French Alzheimer's Foundation to study the ubiquitin-proteasome system, which plays a critical role in protein homeostasis, in transgenic mouse models of AD. She has also received a previous pilot grant from the American Health Assistance Foundation (Brightfocus) to study the role of low-density lipoprotein receptor-related protein (LRP) in AD mouse models. Dr. Xu is an expert on transgenic technology, molecular biology, histology/neuropathology, and proteomics.